Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 153

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 153
---
 non-contingentretainer fee paid monthly for the first two months of Goldman Sachs’ engagement by the Special Committee), and the remainder of which is contingent upon consummation of the Transactions. In addition, the Special Committee has agreed to reimburse Goldman Sachs for certain of its expenses, including attorneys’ fees and disbursements, and to indemnify Goldman Sachs and related persons against various liabilities, including certain liabilities under the federal securities laws. Interests of Enfusion’s Directors and Executive Officers in the Transactions In considering the recommendation of the Enfusion Board that Enfusion Stockholders vote “FOR” the Merger Agreement Proposal, Enfusion Stockholders should be aware that Enfusion’s executive officers and non-employeedirectors have interests in the Transactions that may be different from, or in addition to, those of Enfusion Stockholders generally. The Enfusion Board was aware of and considered these interests, among other matters, in approving the Merger Agreement and the Merger and in recommending that Enfusion Stockholders vote their shares of Enfusion Common Stock and Enfusion Class B Common Stock in favor of the Merger Agreement Proposal and the Adjournment Proposal. Executive Officers and Non-EmployeeDirectors For purposes of this disclosure, Enfusion’s executive officers are:

| Name               |     | Position                              |
| Oleg Movchan       |     | Chief Executive Officer               |
| Neal Pawar         |     | Chief Operating Officer               |
| Bronwen Bastone    |     | Chief People Officer                  |
| Bradley Herring    |     | Chief Financial Officer               |
| Matthew Campobasso |     | General Counsel & Corporate Secretary |

Enfusion’s current non-employeedirectors are Michael Spellacy, Bradford Bernstein, Kathleen Traynor DeRose, Jan Hauser, Larry Leibowitz, Roy Luo and Deirdre Somers. Certain Assumptions Except as otherwise specifically noted, for purposes of quantifying the potential payments and benefits described in this section, the following assumptions were used:

| • |     | the relevant price per share of Enfusion Common Stock is $11.25, which is the implied value per share of Enfusion 
 Common Stock as described in the section titled “Market Price and Dividend Information;”                          |

| • |     | each executive officer of Enfusion experiences a qualifying termination of employment (i.e., a termination of 
 employment by Enfusion and/or Clearwater without “cause” or by the executive officer                          |

97

| • |     | the potential payments and benefits described